2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1076

Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Abstract Number: 1748

Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Abstract Number: 1646

Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution
Abstract Number: 332

Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis
Abstract Number: 453

Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Abstract Number: 1234

Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Abstract Number: 2013

Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Abstract Number: 994

Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants
Abstract Number: 2422

Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome
Abstract Number: 2897

Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Abstract Number: 2863

Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
Abstract Number: 1344

Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study
Abstract Number: 1297

Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies
Abstract Number: 1703

Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease
Abstract Number: 1296

Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].